Evidence mapPaperPMID 33809756Full record

ArticleCancers2021

Hyperglycemia-Induced miR-467 Drives Tumor Inflammation and Growth in Breast Cancer.

Jasmine Gajeton, Irene Krukovets, Santoshi Muppala, Dmitriy Verbovetskiy, Jessica Zhang, Olga Stenina-Adognravi

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Hyperglycemia and microRNAs in prostate cancer.Prostate cancer and prostatic diseases · 2025
    Article
  3. Review
  4. Article
  5. Next-Cell Hypothesis: Mechanism of Obesity-Associated Carcinogenesis.Advances in experimental medicine and biology · 2024
    Review
  6. Obesity as a Risk Factor for Breast Cancer-The Role of miRNA.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. miR-467 regulates inflammation and blood insulin and glucose.Journal of cellular and molecular medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jasmine GajetonDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, 9500 Euclid Avenue NB50, Cleveland, OH 44195, USA.
Irene KrukovetsDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, 9500 Euclid Avenue NB50, Cleveland, OH 44195, USA.
Santoshi MuppalaDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, 9500 Euclid Avenue NB50, Cleveland, OH 44195, USA.
Dmitriy VerbovetskiyDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, 9500 Euclid Avenue NB50, Cleveland, OH 44195, USA.
Jessica ZhangDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, 9500 Euclid Avenue NB50, Cleveland, OH 44195, USA.
Olga Stenina-AdognraviDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, 9500 Euclid Avenue NB50, Cleveland, OH 44195, USA.
Cleveland Clinic · USCase Western Reserve University · US

Funding

American Heart Association 17PRE33660475NIH HHS R01 CA177771NIH HHS R01 HL117216
6 · The paper itself

Abstract

The tumor microenvironment contains the parenchyma, blood vessels, and infiltrating immune cells, including tumor-associated macrophages (TAMs). TAMs affect the developing tumor and drive cancer inflammation. We used mouse models of hyperglycemia and cancer and specimens from hyperglycemic breast cancer (BC) patients to demonstrate that miR-467 mediates the effects of high blood glucose on cancer inflammation and growth. Hyperglycemic patients have a higher risk of developing breast cancer. We have identified a novel miRNA-dependent pathway activated by hyperglycemia that promotes BC angiogenesis and inflammation supporting BC growth. miR-467 is upregulated in endothelial cells (EC), macrophages, BC cells, and in BC tumors. A target of miR-467, thrombospondin-1 (TSP-1), inhibits angiogenesis and promotes resolution of inflammation. Systemic injections of a miR-467 antagonist in mouse models of hyperglycemia resulted in decreased BC growth (

Indexed as

breast cancerhyperglycemiamiRNAtumor-associated macrophages

Identifiers

PMID33809756
PMCPMC8002237
OpenAlexW3136946250

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.